MétaCan
Menu
← Back to cohort
Record W2015965838 · doi:10.1158/1078-0432.ovca13-a84

Abstract A84: Metronomic cyclophosphamide, when combined with vaccination, increases the immunogenicity of the vaccine and modulates the tumor microenvironment to provide better anti-tumor activity

2013· article· en· W2015965838 on OpenAlexaff
Genevieve Weir, Neil L. Berinstein, Оlga Hrytsenko, Mohan Karkada, Marianne M. Stanford, Marc Mansour

Bibliographic record

VenueClinical Cancer Research · 2013
Typearticle
Languageen
FieldImmunology and Microbiology
TopicImmunotherapy and Immune Responses
Canadian institutionsDalhousie UniversitySunnybrook Health Science CentreHealth Sciences CentreImmunovaccine (Canada)
Fundersnot available
KeywordsELISPOTCytotoxic T cellImmune systemImmunologyCD8Tumor microenvironmentImmunogenicityTumor antigenAntigenCTL*Granzyme BCancer vaccineMedicineCancer researchBiologyImmunotherapyIn vitro

Abstract

fetched live from OpenAlex

Abstract DPX-Survivac is a peptide vaccine targeting the broadly expressed tumor antigen survivin. The vaccine contains a mixture of survivin HLA class I peptides (A1, A2, A3, A24 and B7) formulated in the novel adjuvanting vaccine platform DepoVaxTM. A phase I clinical study performed in advanced ovarian cancer patients (n=19) demonstrated that the combination of metronomic cyclophosphamide (mCPA) and DPX-Survivac exhibited enhanced immune responses by IFN-γ ELISPOT (p<0.015) and increased poly-functional antigen-specific EM/ CM CD8+ T cells, relative to patients treated with vaccine alone. These results were mirrored in a preclinical mouse model in which tumor bearing mice treated with mCPA in combination with a DPX peptide vaccine had increased IFN-γ ELISPOT response and enriched antigen-specific CD8+ T cells. Adoptively transferred T cells from mice treated with the combination of mCPA and vaccine provided a more pronounced anti-tumor effect. Immunophenotyping by flow cytometry indicated that mice treated with mCPA and vaccine had reduced levels of tumor-induced immune suppressor cells, such as myeloid derived suppressor cells, but no effect was seen on regulatory T cells. Analysis of the tumor microenvironment by RT-qPCR revealed that mice treated with combination therapy had increased levels of cytotoxic T lymphocyte (CTL) markers such as granzyme B and IFN-γ. An ovarian tumor model (MOSE) was developed in HLA-A2 transgenic mice to extend these finding to a DPX-survivin vaccine in a relevant animal model. We showed that mCPA increased the levels of CTL markers in the tumor specifically when combined with a DPX-survivin vaccine, in addition to enhancing the immunogenicity of the vaccine. Together, these models allow us to explore novel immune modulator/ vaccine combinations and provide insight into mechanisms that could result in enhanced anti-tumor activity. Citation Format: Genevieve M. Weir, Neil L. Berinstein, Olga Hrytsenko, Mohan Karkada, Marianne M. Stanford, Marc Mansour. Metronomic cyclophosphamide, when combined with vaccination, increases the immunogenicity of the vaccine and modulates the tumor microenvironment to provide better anti-tumor activity. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research: From Concept to Clinic; Sep 18-21, 2013; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2013;19(19 Suppl):Abstract nr A84.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.010

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.031
GPT teacher head0.332
Teacher spread0.301 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2013
Admission routes1
Has abstractyes

Explore more

Same venueClinical Cancer Research→Same topicImmunotherapy and Immune Responses→French-language works237,207→